-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Levosimendan in Pulmonary Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Levosimendan in Pulmonary Hypertension report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Levosimendan in Pulmonary Hypertension Drug Details: Levosimendan (Simdax, Zimino) is a...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Imatinib Mesylate in Pulmonary Arterial Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Imatinib Mesylate in Pulmonary Arterial Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Imatinib Mesylate in Pulmonary Arterial Hypertension Drug Details: Imatinib mesylate...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mazdutide in Obesity
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mazdutide in Obesity report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mazdutide in Obesity Drug Details: Mazdutide (LY-3305677) is under development for the treatment...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Levosimendan in Diastolic Heart Failure (HFpEF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Levosimendan in Diastolic Heart Failure (HFpEF) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Levosimendan in Diastolic Heart Failure (HFpEF) Drug Details: Levosimendan (Simdax,...
-
Product Insights
Diastolic Heart Failure – Drugs In Development, 2023
Global Markets Direct’s, ‘Diastolic Heart Failure - Drugs In Development, 2023’, provides an overview of the Diastolic Heart Failure pipeline landscape. The report provides comprehensive information on the therapeutics under development for Diastolic Heart Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Pulmonary Arterial Hypertension – Drugs In Development, 2023
Global Markets Direct’s, ‘Pulmonary Arterial Hypertension - Drugs In Development, 2023’, provides an overview of the Pulmonary Arterial Hypertension pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Pulmonary Hypertension – Drugs In Development, 2023
Global Markets Direct’s, ‘Pulmonary Hypertension - Drugs In Development, 2023’, provides an overview of the Pulmonary Hypertension pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pulmonary Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Continuous Glucose Monitors Pipeline by Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies
Continuous Glucose Monitors Pipeline Market Report Overview The continuous glucose monitoring system helps in the continuous measurement of blood glucose. The Continuous Glucose Monitors pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials. Key Territories ·       The US...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Levosimendan in Diastolic Heart Failure
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Levosimendan in Diastolic Heart Failure report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Levosimendan in Diastolic Heart Failure Drug Details: Levosimendan (Simdax, Zimino) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Imatinib Mesylate in Pulmonary Arterial Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Imatinib Mesylate in Pulmonary Arterial Hypertension report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Imatinib Mesylate in Pulmonary Arterial Hypertension Drug Details: Imatinib...